ABBV climbs around 1.5% after double-digit revenue growth and Apogee acquisition

Traders Union
All News
Stocks
AbbVie rises 1.58% today to $265.96

Highlights

AbbVie delivered double-digit revenue growth year over year, with Skyrizi and Rinvoq sales each up more than 20%.
The company raised its 2026 outlook, projects $21.7 billion in Skyrizi revenue, and completed a $10.9 billion Apogee Therapeutics acquisition.
AbbVie stock trades near session highs at $265.96, with strong bullish momentum and an expected range of $256.63 to $275.28 for the next five days.

Revenue forecast raised as immunology sales and strategic deals drive optimism

AbbVie reported double-digit year-over-year revenue growth in the latest quarter, with significant contributions from its immunology drugs Skyrizi and Rinvoq, both posting sales increases of more than 20%. The company also raised its earnings and revenue outlook for 2026, projecting Skyrizi revenue to reach $21.7 billion. AbbVie completed a $10.9 billion acquisition of Apogee Therapeutics and is moving forward with investigational lung cancer therapies, with new clinical data expected at a future conference. Dividend payouts increased, now at $6.92 per share with a 2.6% yield, and insider trading as well as institutional portfolio adjustments were also noted during the quarter.

Anton Kharitonov, expert at Traders Union, sees AbbVie's solid immunology sales and pipeline advancements as a clear driver of its recent price gains. He notes increased insider trading and portfolio rebalancing as signs of shifting institutional sentiment. Technicals show momentum, but overbought signals from multiple indicators and profit-taking risks are present. Kharitonov highlights potential downside if price breaks below $260.38, as the bullish thesis is vulnerable to reversal. He says, "Despite recent earnings strength, I remain cautious given mixed momentum signals and growing exhaustion risk at these levels."

Viktoras Karapetjanc, expert at Traders Union, observes that AbbVie's strong revenue growth and raised 2026 outlook confirm accelerating business momentum. He points to the successful integration of Apogee Therapeutics and further clinical data as catalysts supporting a robust fundamental story. The bullish structure remains intact, with both dividend increases and portfolio inflows providing further confirmation. He states, "With pipeline tailwinds and broad-based revenue drivers, I expect further growth and believe the market offers multiple upside setups above $266.66."

Jainam Mehta, market strategist, notes that AbbVie’s technicals point to a strong rally but with conflicting momentum and overbought alerts. He sees a consolidation phase unfolding unless $266.66 is taken out with heavy volume. Mehta recognizes a divergence between indicators that may attract contrarian short sellers if exhaustion persists. He says, "A potential breakout above $266.66 could trigger a tactical long entry, but I’m watching for mean reversion signals if sellers regain control near these highs."

Bullish momentum persists as overbought signals and volatility expand

AbbVie is trading above its 20-day, 50-day, and 200-day moving averages ($253.01, $247.19, and $226.3), underlining bullish momentum in the short, medium, and long term. The near-term ceiling is $266.66 and the floor is $260.38, highlighting important levels for traders. MACD and ADX indicate ongoing buying momentum, while the RSI is at 61.59, remaining in the buy zone but not yet overbought. However, CCI and BBP both point to overbought conditions, and the Stochastic RSI signals a strong sell, diverging from other indicators. Intraday activity is near the day's high with 2.41% volatility, suggesting strong session strength but some short-term exhaustion risk.

Earlier, analysts noted that AbbVie’s technical strength and strategic acquisitions positioned the stock for further gains, with attention on its breakout potential. The current analysis builds on that outlook by confirming sustained bullish momentum across multiple timeframes, highlighting a close watch on $266.66 as the key resistance for a potential upside move in the coming days.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.